Oakdale, MN, September 27th, 2021 – Salspera, LLC, a clinical stage biotechnology developing orally administered tumor microbiome immunotherapies, today announced positive topline data from its phase 2 trial of Saltikva in first line metastatic pancreatic cancer. The company also announced that enrollment is ongoing in both study arms.
Eddie Moradian, PhD, Chief Executive Officer of Salspera commented, “We are extremely excited to report positive data from our ongoing phase 2 trial in metastatic pancreatic cancer. We are very pleased with the response rates and impact on the quality of life of these patients. We look forward to fully enrolling this trial to further explore Saltikva’s ability to fight this disease.”
Salspera, LLC is a private, clinical stage biotech company developing its platform of orally administered microbiome immunotherapies in solid tumors. The deep pipeline consists of orally administered microbiome immunotherapies, genetically engineered to eliminate pathogenicity and express various cytokines and cytotoxic proteins within the tumor microenvironment. The lead asset, Saltikva, is currently in an on-going phase 2 clinical study in first line metastatic pancreatic cancer patients in Canada. Salspera's platform consists of numerous constructs engineered to deliver among others, PD-L1, CTLA-4, and IL-15 intra-tumorally.
M. Chandler Glass
Business Development Manager